PERTH, Australia, 4th December 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to provide a strategic update to the market.
As part of the ‘Pivot to Platform’ announced 24 November 2017(link here to presentation) Phylogica will de-prioritise all internal product development programs including the company’s iMyc, Stat5 and YB1 programs in favour of the commercialisation of the Company’s FPP intracellular delivery technology. This decision provides a defined and shorter path to value creation for shareholders through focusing resources on the FPP delivery technology.
For further information please download PDF attached:
Download this document
